{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T04:18:06Z","timestamp":1791433086057,"version":"4.3.3"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32DA007250"],"award-info":[{"award-number":["T32DA007250"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.jad.2023.03.083","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T18:14:38Z","timestamp":1680200078000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":39,"special_numbering":"C","title":["The need for establishing best practices and gold standards in psychedelic medicine"],"prefix":"10.1016","volume":"332","author":[{"given":"Allison","family":"Feduccia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabby","family":"Agin-Liebes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Collin M.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Grinsell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Summer","family":"Paradise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Rabin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2023.03.083_bb0005","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00213-022-06123-7","article-title":"Great expectations: recommendations for improving the methodological rigor of psychedelic clinical trials","volume":"239","author":"Aday","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.03.083_bb0010","first-page":"27","article-title":"Psilocybin-assisted group therapy for demoralized older long-term AIDS survivor men: an open-label safety and feasibility pilot study","author":"Anderson","year":"2020","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.jad.2023.03.083_bb0015","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S2215-0366(20)30146-2","article-title":"Psychedelic medicine: safety and ethical concerns","volume":"7","author":"Anderson","year":"2020","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0020","doi-asserted-by":"crossref","first-page":"105","DOI":"10.31887\/DCNS.2008.10.1\/tcbaghai","article-title":"Electroconvulsive therapy and its different indications","volume":"10","author":"Baghai","year":"2008","journal-title":"Dialogues Clin. Neurosci."},{"key":"10.1016\/j.jad.2023.03.083_bb0025","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1007\/s00787-021-01765-y","article-title":"Minding the gap between clinical guidelines and real-life clinical work","volume":"30","author":"Balan-Moshe","year":"2021","journal-title":"Eur. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0030","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cpt.2487","article-title":"Acute effects of psilocybin after escitalopram or placebo pretreatment in a randomized, double-blind, placebo-controlled, crossover study in healthy subjects","volume":"111","author":"Becker","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.jad.2023.03.083_bb0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/0022167816673493","article-title":"Development of a psychotherapeutic model for psilocybin-assisted treatment of alcoholism","volume":"57","author":"Bogenschutz","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"10.1016\/j.jad.2023.03.083_bb0045","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3389\/fphar.2018.00100","article-title":"Clinical interpretations of patient experience in a trial of psilocybin-assisted psychotherapy for alcohol use disorder","volume":"9","author":"Bogenschutz","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2023.03.083_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamapsychiatry.2022.2096","article-title":"Percentage of heavy drinking days following psilocybin-assisted psychotherapy vs placebo in the treatment of adult patients with alcohol use disorder: a randomized clinical trial","author":"Bogenschutz","year":"2022","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0055","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1093\/jmt\/9.2.64","article-title":"The use of music in psychedelic (LSD) psychotherapy","volume":"9","author":"Bonny","year":"1972","journal-title":"J. Music. Ther."},{"key":"10.1016\/j.jad.2023.03.083_bb0060","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00213-017-4777-4","article-title":"Regulation of human research with LSD in the United States (1949\u20131987)","volume":"235","author":"Bonson","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.03.083_bb0065","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0893-133X(95)00145-4","article-title":"Chronic administration of serotonergic antidepressants attenuates the subjective effects of LSD in humans","volume":"14","author":"Bonson","year":"1996","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2023.03.083_bb0070","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0166-4328(96)00102-7","article-title":"Alterations in responses to LSD in humans associated with chronic administration of tricyclic antidepressants, monoamine oxidase inhibitors or lithium","volume":"73","author":"Bonson","year":"1996","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.jad.2023.03.083_bb0075","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1080\/17460441.2019.1666102","article-title":"Redirecting the revolution: new developments in drug development for psychiatry","volume":"14","author":"Brady","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"key":"10.1016\/j.jad.2023.03.083_bb0080","first-page":"11","article-title":"The gold standard and the pyrite principle: toward a supplemental frame of reference","author":"Brodsky","year":"2020","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2023.03.083_bb0085","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1186\/s12889-018-5351-7","article-title":"The effectiveness and safety of combining varenicline with nicotine e-cigarettes for smoking cessation in people with mental illnesses and addictions: study protocol for a randomised-controlled trial","volume":"18","author":"Bullen","year":"2018","journal-title":"BMC Public Health"},{"key":"10.1016\/j.jad.2023.03.083_bb0090","doi-asserted-by":"crossref","first-page":"3047","DOI":"10.1007\/s00213-022-06221-6","article-title":"Expectancy in placebo-controlled trials of psychedelics: if so, so what?","volume":"239","author":"Butler","year":"2022","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.03.083_bb0095","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1038\/s41586-020-3008-z","article-title":"A non-hallucinogenic psychedelic analogue with therapeutic potential","volume":"589","author":"Cameron","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.jad.2023.03.083_bb0100","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2023.03.083_bb0105","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0110","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1093\/brain\/awq010","article-title":"The default-mode, ego-functions and free-energy: a neurobiological account of Freudian ideas","volume":"133","author":"Carhart-Harris","year":"2010","journal-title":"Brain"},{"key":"10.1016\/j.jad.2023.03.083_bb0115","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00213-014-3714-z","article-title":"LSD enhances suggestibility in healthy volunteers","volume":"232","author":"Carhart-Harris","year":"2015","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.03.083_bb0120","first-page":"13","article-title":"Psychedelic-assisted psychotherapy\u2014a systematic review of associated psychological interventions","author":"Cavarra","year":"2022","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2023.03.083_bb0125","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1136\/bmj.330.7500.1121","article-title":"The gold standard: not a golden standard","volume":"330","author":"Claassen","year":"2005","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2023.03.083_bb0130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/00006842-196507000-00016","article-title":"The beyond within. The LSD story","volume":"27","author":"Cohen","year":"1965","journal-title":"Psychosom. Med."},{"key":"10.1016\/j.jad.2023.03.083_bb0135","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1176\/appi.ajp.2019.19070684","article-title":"A single ketamine infusion combined with motivational enhancement therapy for alcohol use disorder: a randomized midazolam-controlled pilot trial","volume":"177","author":"Dakwar","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0140","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fpsyt.2018.00004","article-title":"Why cognitive behavioral therapy is the current gold standard of psychotherapy","volume":"9","author":"David","year":"2018","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0145","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0150","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1080\/02791072.2002.10399952","article-title":"A clinical plan for MDMA (Ecstasy) in the treatment of posttraumatic stress disorder (PTSD): partnering with the FDA","volume":"34","author":"Doblin","year":"2002","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jad.2023.03.083_bb0155","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1136\/bmj.304.6841.1568-b","article-title":"Time to abolish \u201cgold standard\u201d","volume":"304","author":"Duggan","year":"1992","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2023.03.083_bb0160","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1056\/NEJMra2034954","article-title":"Electroconvulsive therapy","volume":"386","author":"Espinoza","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2023.03.083_bb0165","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00213-020-05710-w","article-title":"Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy","volume":"238","author":"Feduccia","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.03.083_bb0170","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2019.00650","article-title":"Breakthrough for trauma treatment: safety and efficacy of MDMA-assisted psychotherapy compared to paroxetine and sertraline","volume":"10","author":"Feduccia","year":"2019","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0175","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1056\/NEJM198212233072604","article-title":"Double standards, scientific methods, and epidemiologic research","volume":"307","author":"Feinstein","year":"1982","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2023.03.083_bb0180","first-page":"189","article-title":"The adverse effects of hallucinogens from intramural perspective","volume":"8","author":"Frecska","year":"2006","journal-title":"Neuropsychopharmacol. Hung."},{"key":"10.1016\/j.jad.2023.03.083_bb0185","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s00213-020-05719-1","article-title":"Classic serotonergic psychedelics for mood and depressive symptoms: a meta-analysis of mood disorder patients and healthy participants","volume":"238","author":"Galv\u00e3o-Coelho","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.03.083_bb0190","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1080\/09540261.2018.1486289","article-title":"Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions","volume":"30","author":"Garcia-Romeu","year":"2018","journal-title":"Int. Rev. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5498\/wjp.v9.i1.1","article-title":"Electroconvulsive therapy: 80 years old and still going strong","volume":"9","author":"Gazdag","year":"2019","journal-title":"World J. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0200","first-page":"1","article-title":"Electroconvulsive therapy: still the gold standard for highly treatment-resistant mood disorders","author":"Goldberg","year":"2021","journal-title":"CNS Spectr."},{"key":"10.1016\/j.jad.2023.03.083_bb0205","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2023.03.083_bb0210","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1055\/s-2007-979356","article-title":"Methodological issues of human experimental research with hallucinogens","volume":"31","author":"Gouzoulis-Mayfrank","year":"1998","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0215","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/02791072.1986.10472364","article-title":"Subjective reports of the effects of MDMA in a clinical setting","volume":"18","author":"Greer","year":"1986","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jad.2023.03.083_bb0220","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2023.03.083_bb0225","series-title":"Psychedelic Drugs Reconsidered","author":"Grinspoon","year":"1979"},{"key":"10.1016\/j.jad.2023.03.083_bb0230","series-title":"The Human Encounter With Death","author":"Grof","year":"1772"},{"key":"10.1016\/j.jad.2023.03.083_bb0235","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1080\/1751696X.2014.993244","article-title":"Psychoactive substances in prehistoric times: examining the archaeological evidence","volume":"8","author":"Guerra-Doce","year":"2015","journal-title":"Time Mind"},{"key":"10.1016\/j.jad.2023.03.083_bb0240","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2023.03.083_bb0245","series-title":"The Yale Manual for Psilocybin-assisted Therapy of Depression (Using Acceptance and Commitment Therapy as a Therapeutic Frame) (preprint)","author":"Guss","year":"2020"},{"key":"10.1016\/j.jad.2023.03.083_bb0250","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jad.2022.07.004","article-title":"At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: findings from a large, prospective, open-label effectiveness trial","volume":"314","author":"Hull","year":"2022","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2023.03.083_bb0255","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1177\/0269881108093587","article-title":"Human hallucinogen research: guidelines for safety","volume":"22","author":"Johnson","year":"2008","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2023.03.083_bb0260","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1177\/0269881114548296","article-title":"Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction","volume":"28","author":"Johnson","year":"2014","journal-title":"J. Psychopharmacol. Oxf. Engl."},{"key":"10.1016\/j.jad.2023.03.083_bb0265","doi-asserted-by":"crossref","first-page":"55","DOI":"10.3109\/00952990.2016.1170135","article-title":"Long-term follow-up of psilocybin-facilitated smoking cessation","volume":"43","author":"Johnson","year":"2017","journal-title":"Am. J. Drug Alcohol Abuse"},{"key":"10.1016\/j.jad.2023.03.083_bb0270","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1016\/S0140-6736(15)60742-5","article-title":"The history and fate of the gold standard","volume":"385","author":"Jones","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jad.2023.03.083_bb0275","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1038\/s41598-021-81446-7","article-title":"Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing","volume":"11","author":"Kaertner","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jad.2023.03.083_bb0280","doi-asserted-by":"crossref","first-page":"31858","DOI":"10.3402\/ejpt.v7.31858","article-title":"PTSD: from neurobiology to pharmacological treatments","volume":"7","author":"Kelmendi","year":"2016","journal-title":"Eur. J. Psychotraumatol."},{"key":"10.1016\/j.jad.2023.03.083_bb0285","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1001\/archpsyc.62.6.617","article-title":"Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication","volume":"62","author":"Kessler","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0290","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1080\/02791072.1997.10400185","article-title":"Ketamine psychedelic therapy (KPT): a review of the results of ten years of research","volume":"29","author":"Krupitsky","year":"1997","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jad.2023.03.083_bb0295","article-title":"Psychedelic innovations and the crisis of psychopharmacology","author":"Langlitz","year":"2022","journal-title":"BioSocieties"},{"key":"10.1016\/j.jad.2023.03.083_bb0300","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1002\/hbm.22833","article-title":"Finding the self by losing the self: neural correlates of ego-dissolution under psilocybin","volume":"36","author":"Lebedev","year":"2015","journal-title":"Hum. Brain Mapp."},{"key":"10.1016\/j.jad.2023.03.083_bb0305","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/02791072.2020.1769878","article-title":"A meta-analysis of placebo-controlled trials of psychedelic-assisted therapy","volume":"52","author":"Luoma","year":"2020","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jad.2023.03.083_bb0310","first-page":"212","article-title":"Patents on psychedelics: the next legal battlefront of drug development","volume":"135","author":"Marks","year":"2021","journal-title":"Harv. Law Rev. Forum"},{"key":"10.1016\/j.jad.2023.03.083_bb0315","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1001\/jamapsychiatry.2019.1702","article-title":"Association with hospitalization and all-cause discontinuation among patients with schizophrenia on clozapine vs other oral second-generation antipsychotics: a systematic review and meta-analysis of cohort studies","volume":"76","author":"Masuda","year":"2019","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0320","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.868103","article-title":"Toward synergies of ketamine and psychotherapy","volume":"13","author":"Mathai","year":"2022","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2023.03.083_bb0325","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.jaac.2010.05.017","article-title":"Lifetime prevalence of mental disorders in U.S. adolescents: results from the National Comorbidity Survey Replication-Adolescent Supplement (NCS-A)","volume":"49","author":"Merikangas","year":"2010","journal-title":"J. Am. Acad. Child Adolesc. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0330","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/s41591-021-01336-3","article-title":"MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study","volume":"27","author":"Mitchell","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jad.2023.03.083_bb0335","series-title":"A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder; Version 8.1","author":"Mithoefer","year":"2016"},{"key":"10.1016\/j.jad.2023.03.083_bb0340","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacol. Berl."},{"key":"10.1016\/j.jad.2023.03.083_bb0345","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s00213-019-05249-5","article-title":"MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials","volume":"236","author":"Mithoefer","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.03.083_bb0350","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13011-017-0126-1","article-title":"History of medication-assisted treatment and its association with initiating others into injection drug use in San Diego, CA","volume":"12","author":"Mittal","year":"2017","journal-title":"Subst. Abuse Treat. Prev. Policy"},{"key":"10.1016\/j.jad.2023.03.083_bb0355","first-page":"12","article-title":"Therapeutic alliance and rapport modulate responses to psilocybin assisted therapy for depression","author":"Murphy","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.jad.2023.03.083_bb0360","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1080\/17512433.2021.1933434","article-title":"Blinding and expectancy confounds in psychedelic randomized controlled trials","volume":"14","author":"Muthukumaraswamy","year":"2021","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.jad.2023.03.083_bb0365","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/ajhp\/zxaa303","article-title":"ASHP therapeutic position statement on the use of antipsychotic medications in the treatment of adults with schizophrenia and schizoaffective disorder","volume":"77","author":"Noel","year":"2020","journal-title":"Am. J. Health Syst. Pharm."},{"key":"10.1016\/j.jad.2023.03.083_bb0370","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1353\/ppp.2021.0032","article-title":"Containment matters: set and setting in contemporary psychedelic psychiatry","volume":"28","author":"Noorani","year":"2021","journal-title":"Philos. Psychiatry Psychol."},{"key":"10.1016\/j.jad.2023.03.083_bb0375","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2016.00269","article-title":"Ego-dissolution and psychedelics: validation of the ego-dissolution inventory (EDI)","volume":"10","author":"Nour","year":"2016","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.jad.2023.03.083_bb0380","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/papr.12829","article-title":"Ketamine and cognitive behavioral therapy for rapid opioid tapering with sustained opioid abstinence: a case report and 1-year follow-up","volume":"20","author":"Ocker","year":"2020","journal-title":"Pain Pract."},{"key":"10.1016\/j.jad.2023.03.083_bb0385","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1177\/0269881112464827","article-title":"A randomized, controlled pilot study of MDMA (\u00b13,4-methylenedioxymethamphetamine)-assisted psychotherapy for treatment of resistant, chronic post-traumatic stress disorder (PTSD)","volume":"27","author":"Oehen","year":"2013","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2023.03.083_bb0390","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1111\/j.1749-6632.1957.tb40738.x","article-title":"A review of the clinical effects of psychotomimetic agentS","volume":"66","author":"Osmond","year":"1957","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.jad.2023.03.083_bb0395","first-page":"149","article-title":"Psychedelic drugs and mystical experience","volume":"5","author":"Pahnke","year":"1969","journal-title":"Int. Psychiatry Clin."},{"key":"10.1016\/j.jad.2023.03.083_bb0400","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1001\/jama.1970.03170240060010","article-title":"The experimental use of psychedelic (LSD) psychotherapy","volume":"212","author":"Pahnke","year":"1970","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2023.03.083_bb0405","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2022.1020505","article-title":"Lower-dose psycholytic therapy - a neglected approach","volume":"13","author":"Passie","year":"2022","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0410","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12954-021-00489-1","article-title":"Ethical and legal issues in psychedelic harm reduction and integration therapy","volume":"18","author":"Pilecki","year":"2021","journal-title":"Harm Reduct. J."},{"key":"10.1016\/j.jad.2023.03.083_bb0415","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0022167816670996","article-title":"Psychedelic psychotherapy: insights from 25 years of research","volume":"57","author":"Richards","year":"2017","journal-title":"J. Humanist. Psychol."},{"key":"10.1016\/j.jad.2023.03.083_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fnhum.2014.00204","article-title":"The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers","volume":"8","author":"Roseman","year":"2014","journal-title":"Front. Hum. Neurosci."},{"key":"10.1016\/j.jad.2023.03.083_bb0425","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2023.03.083_bb0430","series-title":"Neuropharmacology, Psychedelics: New Doors, Altered Perceptions","first-page":"200","article-title":"Psychiatry & the psychedelic drugs. Past, present & future","volume":"142","author":"Rucker","year":"2018"},{"key":"10.1016\/j.jad.2023.03.083_bb0435","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-022-06083-y","article-title":"Drug-drug interactions between psychiatric medications and MDMA or psilocybin: a systematic review","author":"Sarparast","year":"2022","journal-title":"Psychopharmacology (Berl.)"},{"key":"10.1016\/j.jad.2023.03.083_bb0440","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1080\/13651500600552487","article-title":"Evidence-based treatment of anxiety disorders","volume":"10","author":"Stein","year":"2006","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.jad.2023.03.083_bb0445","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.586682","article-title":"Development and evaluation of a therapist training program for psilocybin therapy for treatment-resistant depression in clinical research","volume":"12","author":"Tai","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0450","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s00213-006-0576-z","article-title":"The effects of fluoxetine on the subjective and physiological effects of 3,4-methylenedioxymethamphetamine (MDMA) in humans","volume":"189","author":"Tancer","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2023.03.083_bb0455","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40345-019-0151-2","article-title":"Clinical use of lithium salts: guide for users and prescribers","volume":"7","author":"Tondo","year":"2019","journal-title":"Int. J. Bipolar Disord."},{"key":"10.1016\/j.jad.2023.03.083_bb0460","series-title":"Examining the Dark Sides of Psychedelic Therapy","first-page":"34","author":"Villeneuve","year":"2022"},{"key":"10.1016\/j.jad.2023.03.083_bb0465","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2020.00377","article-title":"Lithium treatment over the lifespan in bipolar disorders","volume":"11","author":"Volkmann","year":"2020","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0470","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.702838","article-title":"Relational and growth outcomes following couples therapy with MDMA for PTSD","volume":"12","author":"Wagner","year":"2021","journal-title":"Front. Psychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0475","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1159\/000517074","article-title":"Cognitive behavioral therapy to sustain the antidepressant effects of ketamine in treatment-resistant depression: a randomized clinical trial","volume":"90","author":"Wilkinson","year":"2021","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2023.03.083_bb0480","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1159\/000457960","article-title":"Cognitive behavior therapy may sustain antidepressant effects of intravenous ketamine in treatment-resistant depression","volume":"86","author":"Wilkinson","year":"2017","journal-title":"Psychother. Psychosom."},{"key":"10.1016\/j.jad.2023.03.083_bb0485","first-page":"457","article-title":"Medications for alcohol use disorder","volume":"93","author":"Winslow","year":"2016","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.jad.2023.03.083_bb0490","series-title":"The Ketamine Papers: Science, Therapy, and Transformation","author":"Wolfson","year":"2016"},{"key":"10.1016\/j.jad.2023.03.083_bb0495","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2019-1682","article-title":"ADHD diagnosis and treatment guidelines: a historical perspective","volume":"144","author":"Wolraich","year":"2019","journal-title":"Pediatrics"},{"key":"10.1016\/j.jad.2023.03.083_bb0500","series-title":"World Health Organization: Depression Fact Sheet","year":"2021"},{"key":"10.1016\/j.jad.2023.03.083_bb0505","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1055\/s-0043-124872","article-title":"Comparative efficacy and safety of antipsychotic drugs for tic disorders: a systematic review and Bayesian network meta-analysis","volume":"52","author":"Yang","year":"2019","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.jad.2023.03.083_bb0510","doi-asserted-by":"crossref","first-page":"958","DOI":"10.30773\/pi.2021.0209","article-title":"Psilocybin for end-of-life anxiety symptoms: a systematic review and meta-analysis","volume":"18","author":"Yu","year":"2021","journal-title":"Psychiatry Investig."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723004378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032723004378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T03:57:04Z","timestamp":1759031824000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032723004378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":101,"alternative-id":["S0165032723004378"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2023.03.083","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The need for establishing best practices and gold standards in psychedelic medicine","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2023.03.083","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}